Alzheimer’s disease
Connect with Alzheimer’s patients across the globe
Globally, almost 10 million new cases of dementia are diagnosed every year, with Alzheimer’s disease accounting for 60-70% of cases.
While the number of diagnosed patients continues to grow, clinical trials on Alzheimer’s disease in particular are facing a critical shortfall of eligible patients. We’ve performed Alzheimer’s disease patient recruitment for 10+ international trials, from Phase II to Phase III – we know how to find the right candidates for your study.
new cases each year
international trials (phase II & III)
million people diagnosed with diabetes worldwide (2021)
Challenges when recruiting patients for diabetes studies
50% (232 million) of people with diabetes are undiagnosed (according to the International Diabetes Federation).
Therefore, it is hard to reach patients without specific outreach methods.
Newly diagnosed people often do not feel sick or in need of treatment.
Studies show that many patients (especially from minority groups) do not know about diabetes symptoms due to less access to healthcare, education, and lower socioeconomic status. Another barrier is what researchers describe as ‘Diabetes Denial,’ meaning many patients ignore mild symptoms.
Many trials do not provide patient-centric information.
Details on inclusion and exclusion criteria, the goals and procedure of the study, and other information are often not provided in a patient-centric manner. This leads to lower sign-up and participation rates, as well as higher drop-out during a clinical trial.
18-44 years of age
45-64 years of age
>65 years of age
Alzheimer’s disease
Reach patients and caregivers across the globe
Those within the early stages of Alzheimer’s disease wish to hold onto their independence for as long as possible, while those further along require additional care and are more difficult to reach and engage.
That’s why at Clariness, we target both patients and caregivers, which provides much higher engagement and participation willingness. In fact, within a recent survey of 600 participants across 21 countries, 85% of respondents were caregivers.
Alzheimer’s disease
Section title
Lorem ipsum dolor sit amet consectetur adipiscing elit libero metus nulla vel, vivamus sagittis non nisi arcu sem aenean accumsan pellentesque commodo, lectus taciti integer porta sollicitudin torquent volutpat nascetur tincidunt ante. Orci et facilisis vehicula magna ac cum potenti eros quis hac, feugiat penatibus mi morbi torquent purus aenean vivamus cras, risus dapibus scelerisque venenatis tincidunt primis tempus semper massa. Interdum odio himenaeos feugiat fusce pharetra consequat non platea dictumst facilisi vitae et mattis viverra, lobortis maecenas at purus tortor venenatis cras penatibus sollicitudin potenti pulvinar cum.
Lorem ipsum dolor sit amet consectetur adipiscing elit libero metus nulla vel, vivamus sagittis non nisi arcu sem aenean accumsan pellentesque commodo, lectus taciti integer porta sollicitudin torquent volutpat nascetur tincidunt ante. Orci et facilisis vehicula magna ac cum potenti eros quis hac, feugiat penatibus mi morbi torquent purus aenean vivamus cras, risus dapibus scelerisque venenatis tincidunt primis tempus semper massa. Interdum odio himenaeos feugiat fusce pharetra consequat non platea dictumst facilisi vitae et mattis viverra, lobortis maecenas at purus tortor venenatis cras penatibus sollicitudin potenti pulvinar cum.
Alzheimer’s disease
Special screening techniques
Our targeting techniques drive high volumes of traffic to our customized screeners, leading to higher numbers of referred and randomized patients for Alzheimer’s disease studies.
For example, one campaign drove 800k+ visits to our screener that consisted of multiple questions assessing medical eligibility, including I/E criteria, diagnosis, and symptoms.
Ensuring a high scheduling rate, we also provide a customized phone screener that covers participation willingness and a detailed assessment of medication history. This helps to limit study delays and ensures more consented and randomized patients.
Alzheimer’s disease
Find patients aligned to your protocol
Most patients with Alzheimer’s disease are 65+ years old – although early-onset Alzheimer’s can develop earlier.
We reach patients with mild to severe stages of Alzheimer’s disease, as well as their caregivers. We target these patients at stages within their lives where Alzheimer’s is most common.
Our Chief Medical Officer reviews your protocol and aligns with our patient recruitment team. We develop and create objectives and tactics to ensure that patients referred to your sites fit the exact requirements of your study.
How we can help
How can Clariness support my dermatology studies?
We have several options:
1. List your study on our global patient portal, ClinLife®
2. List your study on ClinLife® and launch a tailored recruitment campaign
Interested in a strategy session to discuss how we can tailor a campaign for you?
2021 Patient’s Voice participant
Explore insights
Case Study
PTSD case study
Case Study
Winter indications case studies
How we can help
Our services and solutions
Leverage our experts, data and platforms, to accelerate your clinical trials
Demographic
- Gender, age, ethnicity, social-economic class, location, and other demographics are used as filters to find patients (and their families) most likely to match the study.
Location
- We reach patients living in an area with a high prevalence of diabetes (and related causes and symptoms) and within a predesignated radius around active sites.
Interest
- Patients searching or engaging (e.g., likes, shares, comments, etc.) with diabetes-indication related content and symptoms are shown study advertisements.
Database
- We email our large database of over 1.3 million registered users based on their location and indication. By continuously analyzing the (anonymized) behavior of those successfully enrolled, we can understand and reach similar people.
Services & Solutions
Addressing patient diversity
Minorities are underrepresented in all clinical trials, including many vaccine trials.
Historically, marginalized populations are underrepresented in Alzheimer’s disease clinical trials – despite evidence that these populations may be at increased risk of developing dementia. These include patients that identify as racial or ethnic minorities and those with low socioeconomic status or are living in rural areas.
Informed by Patient Insights, our Alzheimer’s disease patient recruitment and retention services allow us to reach a more diverse population. We use digital tools and multiple communication channels to reduce physical barriers to site access, create patient-friendly study materials to increase health literacy, and tailor strategies to local communities and cultures.
By understanding patient needs, we can overcome the unique barriers these patients face when joining clinical trials.
Services & Solutions
Find patients aligned to your protocol
Embracing new decentralized clinical trial (DCT) solutions in your clinical trial improves the diagnosis and assessment of Alzheimer’s disease.
Case study
Our diabetes case studies
Learn how we’ve supported sponsors with their patient recruitment for diabetes studies, across the globe, resulting in more engagement, more referrals, at less than the budgeted costs:
- Over 2,100 ClinLife referrals
- Successful targeting of patient subpopulation
- Our campaign generated >1.6 million ClinLife website visits
- RWE-driven strategy from 100k patients in 46 countries
Please note that we will not share your data with any 3rd parties, data submitted will be used in accordance with our data privacy policy.
Contact us
Are you designing a diabetes clinical trial, or have one underway?
We can help you find the right patients, at the right time. To find out more about our heart failure patient recruitment, contact us.